GlassScriptPhysician profile
Mohitkumar Ardeshana
NPI 1467867135
$10,141.29
in general payments reported to CMS, 2019-2025
46 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $1,358 · 2021: $2,207 · 2022: $1,773 · 2023: $1,152 · 2024: $1,646 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,209 · Education: $3.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,209.37 |
| Education | $3.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,788.71 | 2021-2025 | Qulipta, Vraylar |
| Novo Nordisk INC | $1,265.27 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $947.86 | 2019-2025 | |
| Lilly USA, LLC | $719.84 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $659.09 | 2019-2024 | |
| Amarin Pharma, INC. | $560.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $541.70 | 2021-2025 | Xifaxan |
| Amgen INC. | $504.71 | 2019-2025 | Evenity, Prolia, Tepezza |
| Horizon Therapeutics Plc | $420.24 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.71 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $238.31 | 2022 | |
| Allergan, INC. | $238.15 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $209.18 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $161.41 | 2020-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $156.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohitkumar Ardeshana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.